Abstract:ABSTRACT Cefepime/enmetazobactam is a new β-lactam/β-lactamase inhibitor combination with broad-spectrum activity against multidrug-resistant Enterobacterales, including OXA-48-producing isolates. Furthermore, cefepime and enmetazobactam have demonstrated similar and excellent intrapulmonary penetration, supporting the use of this new antibiotic combination in the treatment of hospital-acquired pneumonia. This study evaluated the in vivo efficacy of cefepime/enmetazobactam in a murine neutropenic pneumonia model infected with various OXA-48-producing K. pneumoniae strains. Mice were subcutaneously administered with cefepime (100 mg/kg/q2h), alone or combined with enmetazobactam (30 mg/kg/q2h), or intraperitoneally with meropenem (100 mg/kg/q2h) at 2 h post-infection. Mice were euthanized at 26 h post-infection for bacterial enumeration in lungs and spleen. A robust growth was achieved in untreated control mice. Cefepime alone or meropenem had no effect on reducing the bacterial burden in lungs after a 24-h period of treatment. The addition of enmetazobactam to cefepime resulted in a 2-log 10 CFU/g bioburden reduction in lungs compared to 26-h controls for all strains, including the strain harboring the highest MIC (= 8 μg/mL) to cefepime/enmetazobactam. When changes of bacterial burden were assessed relative to 2-h controls, bacterial stasis was observed. These data highlight the limited in vivo activity of meropenem against OXA-48-producing Enterobacterales despite in vitro susceptibility. Conversely, cefepime/enmetazobactam with a human-mimicking regimen demonstrated a significant antibacterial effect in the pneumonia model induced by three OXA-48-producing K. pneumoniae strains, compared with cefepime or meropenem at 24 h post-infection. Therefore, cefepime/enmetazobactam may be a new alternative for lung infections due to Enterobacterales producing OXA-48. IMPORTANCE Third-generation cephalosporin-resistant Klebsiella pneumoniae with extended-spectrum β-lactamases as principal resistance determinants are classified as critical priority pathogens. Their increasing occurrence has led clinicians to widely use carbapenems. Accordingly, carbapenem resistance in Klebsiella pneumoniae has spread in recent decades across several countries, and OXA-48-like carbapenemases are one of the main determinants of carbapenem resistance in Enterobacterales. Cefepime/enmetazobactam is a novel β-lactam/β-lactamase inhibitor combination that demonstrated excellent intrapulmonary penetration, supporting its use in the treatment of pneumonia. This study examined the efficacy of enmetazobactam, in combination with cefepime, compared to carbapenems for OXA-48-producing Klebsiella pneumoniae in a 24-h murine neutropenic pneumonia model. The combination showed a bacteriostatic effect using the 2-h controls as reference. Compared to 24-h controls, and to cefepime or meropenem monotherapies, the co-administration of enmetazobactam with cefepime demonstrated a pronounced in vivo bactericidal activity against cefepime-non-susceptible K. pneumoniae isolates with cefepime/enmetazobactam MICs up to 8 μg/mL in this model.

Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae

Pharmacokinetics/pharmacodynamics of polymyxin B in patients with bloodstream infection caused by carbapenem-resistant <i>Klebsiella pneumoniae</i>

In Vitro Activities of Ertapenem (MK-0826) against Recent Clinical Bacteria Collected in Europe and Australia

Pharmacokinetic/pharma-codynamic study of pralurbactam (FL058) combined with meropenem in a neutropenic murine thigh infection model

Model-informed drug development of benapenem: Pharmacokinetic/Pharmacodynamic cutoff value determination and antibacterial efficacy against enterobacteriaceae.

Pharmacokinetic/pharmacodynamic (PK/PD) of Tebipenem against Klebsiella pneumoniae in Murine Thigh Infection Model

Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against <i>Enterobacteriaceae</i>

Ertapenem's therapeutic potential for Mycobacterium avium lung disease in the hollow fibre model

Efficacy of CS-834 against experimental pneumonia caused by penicillin-susceptible and -resistant Streptococcus pneumoniae in mice

Pharmacokinetic/pharmacodynamic study of tebipenem pivoxil against Klebsiella pneumoniae in murine lung infection model

Antibacterial efficacy of an ultra-short palmitoylated random peptide mixture in mouse models of infection by carbapenem-resistant Klebsiella pneumoniae

In vivo efficacy of enmetazobactam combined with cefepime in a murine pneumonia model induced by OXA-48-producing Klebsiella pneumoniae

Apramycin efficacy against carbapenem- and aminoglycoside-resistant Escherichia coli and Klebsiella pneumoniae in murine bloodstream infection models

Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model

Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia

In Vitro Dynamic Model Evaluation of Meropenem Alone and in Combination with Avibactam Against Carbapenemase-Producing Klebsiella pneumoniae

Apramycin efficacy in the treatment of carbapenem-resistant Enterobacterales in murine blood stream infection models

Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration

Assessing the ability of Tigecycline and Meropenem to clear intra-macrophage Klebsiella pneumoniae

Activity of Meropenem-Vaborbactam in Mouse Models of Infection Due to KPC-Producing Carbapenem-Resistant Enterobacteriaceae